BLAU FARMACÊUTICA S.A. Interim Financial Information (unaudited)
Individual and Consolidated
Blau Farmacêutica S.A.
March 31, 2021
with Independent Auditors' Report
Blau Farmacêutica S.A.
Interim Financial Information (unaudited)
March 31, 2021
Contents
Report on the review of quarterly information | .......................................................................................3 |
Statements of financial position............................................................................................................ | 5 |
Statements of profit or loss .................................................................................................................. | 7 |
Statements of comprehensive income ................................................................................................ | 8 |
Statements of changes in equity .......................................................................................................... | 9 |
Statements of cash flows - indirect method ....................................................................................... | 10 |
Statements of value added ................................................................................................................ | 11 |
Notes to the interim financial statements ........................................................................................... | 12 |
A free translation from Portuguese into English of Independent Auditor's Review Report on Quarterly Information prepared in Brazilian currency in accordance with NBC TG 21 and IAS 34 - Interim Financial Reporting, and with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)
Report on the review of interim financial information
The Shareholders and Officers
Blau Farmacêutica S.A.
Cotia - SP
Introduction
We have reviewed the interim individual and consolidated financial information of Blau Farmacêutica S.A. (the "Company") contained in the Quarterly Information Form - ITR form as of March 31, 2021, which comprise the statement of financial position on March 31, 2021, and the statements of operations, of comprehensive income (loss) and the statements of changes in equity and of cash flows for the three-month period then ended, including explanatory notes.
Management is responsible for the preparation of the individual and consolidated interim financial information in accordance with the NBC TG 21 - Interim Financial Reporting and the international standard IAS 34 - Interim Financial Reporting issued by the International Accounting Standards Board (IASB), as well as for the presentation of this information in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.
Scope of review
We conducted our review in accordance with the Brazilian and international standards on review engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Conclusion on the individual and consolidated interim financial information
Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the quarterly information referred to above was not prepared, in all material respects, in accordance with the NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).
3
Other matters
Audit and review of the corresponding amounts
The examination of the individual and consolidated financial statements as of December 31, 2020 and the review of individual and consolidated interim financial information for the quarter ended March 31, 2020, presented for comparison purposes, were conducted under the responsibility of another independent auditor who issued an audit and review report without modifications, with dates of February 5, 2021 and April 16, 2020, respectively.
Statements of value added
The quarterly information referred to above includes the individual and consolidated statements of value added (DVA) for the three-month period ended March 31, 2021, prepared under the responsibility of the Company management and presented as supplementary information under IAS
34. These statements have been subject to review procedures performed in conjunction with the review of the quarterly information, in order to determine whether they are reconciled with the interim financial information and accounting records, as applicable, and whether their form and content are in accordance with the criteria defined in NBC TG 09 - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not prepared, in all material respects, in accordance with the criteria set forth by this Standard and consistently with the individual and consolidated interim financial information taken as a whole.
São Paulo, May 10, 2021.
ERNST & YOUNG
Auditores Independentes S.S.
CRC-2SP034519/O-6
Márcio D. Berstecher
Accountant CRC-1SP259735/O-2
4
Blau Farmacêutica S.A.
Statements of financial position
March 31, 2021 and December 31, 2020 (In thousands of Reais - R$)
Note | Consolidated | Individual | |||
03/31/2021 | 12/31/2020 | 03/31/2021 | 12/31/2020 | ||
Assets | |||||
Current Assets | |||||
Cash and cash equivalents | 6 | 5,866 | 70,197 | 1,412 | 65,852 |
Investments | 7 | 230,160 | 144,152 | 221,523 | 135,435 |
Trade accounts receivable | 8 | 293,644 | 247,552 | 290,460 | 243,124 |
Inventories | 9 | 360,540 | 327,494 | 342,683 | 312,030 |
Recoverable taxes | 10 | 2,374 | 4,260 | 584 | 3,028 |
Other receivables | 11 | 19,099 | 6,840 | 18,863 | 6,762 |
Total current assets | 911,683 | 800,495 | 875,525 | 766,231 | |
Non-current assets | |||||
Recoverable taxes | 10 | 20,029 | 13,763 | 20,029 | 13,763 |
Judicial deposits | 23 | 6,119 | 6,016 | 6,119 | 6,016 |
Deferred income tax and social contribution | 19 | 11,474 | 15,866 | 11,060 | 15,460 |
Other receivables | 11 | 5,727 | 9,379 | 4,055 | 4,855 |
Investments | 12 | 29 | 29 | 189,857 | 184,158 |
Biological assets | 306 | 306 | 306 | 306 | |
Property, plant and equipment | 13 | 298,429 | 256,740 | 287,254 | 253,394 |
Intangible assets | 14 | 174,606 | 170,031 | 28,132 | 23,940 |
Total non-current assets | 516,719 | 472,130 | 546,812 | 501,892 |
Total assets | 1,428,402 | 1,272,625 | 1,422,337 | 1,268,123 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Blau Farmaceutica SA published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 22:12:01 UTC.
